114 related articles for article (PubMed ID: 10801494)
1. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the protease domain of urokinase-type plasminogen activator.
Rockway TW; Nienaber V; Giranda VL
Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
5. Discovering novel ligands for macromolecules using X-ray crystallographic screening.
Nienaber VL; Richardson PL; Klighofer V; Bouska JJ; Giranda VL; Greer J
Nat Biotechnol; 2000 Oct; 18(10):1105-8. PubMed ID: 11017052
[TBL] [Abstract][Full Text] [Related]
6. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
7. Species specificity of amidine-based urokinase inhibitors.
Klinghofer V; Stewart K; McGonigal T; Smith R; Sarthy A; Nienaber V; Butler C; Dorwin S; Richardson P; Weitzberg M; Wendt M; Rockway T; Zhao X; Hulkower KI; Giranda VL
Biochemistry; 2001 Aug; 40(31):9125-31. PubMed ID: 11478879
[TBL] [Abstract][Full Text] [Related]
8. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
9. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
Zeslawska E; Schweinitz A; Karcher A; Sondermann P; Sperl S; Stürzebecher J; Jacob U
J Mol Biol; 2000 Aug; 301(2):465-75. PubMed ID: 10926521
[TBL] [Abstract][Full Text] [Related]
10. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
12. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
13. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
14. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
[TBL] [Abstract][Full Text] [Related]
15. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
[TBL] [Abstract][Full Text] [Related]
16. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
17. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
19. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
Bruncko M; McClellan WJ; Wendt MD; Sauer DR; Geyer A; Dalton CR; Kaminski MA; Weitzberg M; Gong J; Dellaria JF; Mantei R; Zhao X; Nienaber VL; Stewart K; Klinghofer V; Bouska J; Rockway TW; Giranda VL
Bioorg Med Chem Lett; 2005 Jan; 15(1):93-8. PubMed ID: 15582418
[TBL] [Abstract][Full Text] [Related]
20. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]